Gepotidacin is the first in a new class of oral antibiotics for uUTIs in nearly 30 years. The approval was supported by results of the phase 3 EAGLE-2 and EAGLE-3 trials. The FDA approved ...

GSK's Blujepa (gepotidacin) becomes the first in a new class of oral antibiotics to treat uncomplicated UTIs (also known as uUTIs) in almost 30 years, taking aim at infection-causing bacteria ...

The regulatory decision announced Tuesday covers the treatment of female adults and pediatric patients age 12 and older who have uncomplicated urinary tract infections, or uUTIs. The drug ...

The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in adult women and ...

GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. A commercial launch ...

The FDA has approved GSK’s Blujepa (gepotidacin), a first-in-class oral antibiotic for the treatment of uncomplicated urinary tract infections (uUTIs) in female adults and patients over 12 years of ...

Keskusta vankisti entisestään asemaansa Siilinjärven kunnanvaltuustossa, kun se onnistui saamaan itselleen kolme lisäpaikkaa.

Kangasniemeläinen lastenkirjailija Maria Kuutti vieraili Pöljän koulun päiväkodissa kertomassa kirjoistaan ja kirjan tekemisestä. Pöljän päiväkodin eskarilaiset olivat odottaneet vierailua innolla ja ...

Gepotidacin is the first new class of oral antibiotics for uUTIs in nearly 30 years, addressing rising drug resistance. Phase 3 trials showed gepotidacin's non-inferiority to nitrofurantoin ...

TUESDAY, March 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult ...